Postoperative chemotherapy after conversion surgery for clinical stage IV gastric cancer: a propensity score-matched analysis.

Background: Conversion surgery following systemic chemotherapy has emerged as a promising strategy for clinical stage IV gastric cancer. However, the role of postoperative chemotherapy in improving survival outcomes remains unclear. This study aimed to evaluate the impact of postoperative chemotherapy on survival, comparing single-agent and combination regimens.

Impact of prophylactic 5-hydroxytryptamine-3 receptor antagonist on postoperative nausea and vomiting in patients undergoing laparoscopic or robotic colorectal cancer surgery: a propensity score-matched analysis.

Purpose: Postoperative nausea and vomiting (PONV) is a common complication of surgery. This study evaluated the efficacy of prophylactic 5-hydroxytryptamine-3 receptor antagonist (5HT3RA) in preventing PONV in patients undergoing laparoscopic or robotic colorectal cancer (CRC) surgery.

Methods: Between April and June, 2022, 100 consecutive patients received 5HT3RA prophylaxis before anesthesia induction.

The learning curve for single-incision laparoscopic colectomy for colon cancer: succession of surgical techniques for novice surgeons.

Purpose: Single-incision laparoscopic surgery (SILS) for colon cancer is technically challenging for novice surgeons. Although it has been shown to be safe and feasible, the learning curve (LC) among novices has not been characterized. The present study investigated the LC for SILS based on data from several novice surgeons.

Clinical and prognostic characteristics of metastatic colorectal cancer with minor mutations.

Metastatic colorectal cancer (mCRC) presents notable therapeutic challenges. Rat sarcoma virus () mutations, including those in exon 2, are critical for treatment decisions; however, the role of minor mutations ( exons 3 and 4, and ) remains underexplored. Because these mutations are increasingly identified in routine practice due to advances in mutation testing that now routinely includes exons 3 and 4, and , clarifying their clinical relevance has become important for ensuring appropriate treatment selection.

Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study.

Aim: Nivolumab, approved for adjuvant therapy in resected esophageal cancer, is typically administered at 240 mg every 2 weeks (Q2W) or 480 mg every 4 weeks (Q4W). However, data on the 480 mg Q4W regimen as an initial therapy are limited. In this study, we evaluated its safety and efficacy.

Clinical outcomes of pembrolizumab plus chemotherapy for postoperative recurrent esophageal squamous cell carcinoma.

Background: Immunotherapy combined with chemotherapy has been the first-line treatment for metastatic or unresectable locally advanced esophageal cancer. However, postoperative recurrences have not been sufficiently investigated. We investigated the clinical outcomes of pembrolizumab plus cisplatin plus 5-fluorouracil (CF) therapy for postoperative recurrent esophageal squamous cell carcinoma.

Short- and long-term outcomes of robotic versus conventional laparoscopic surgery for middle or lower rectal cancer: a propensity score-matched analysis.

Purpose: The potential benefits of robotic surgery (RS) for rectal cancer (RC) remain uncertain. The objective of this study was to evaluate the short- and long-term outcomes of RS compared to conventional laparoscopic surgery (LS) for stage I-III middle or lower RC.

Methods: This study retrospectively analyzed 350 consecutive patients with stage I-III middle or lower RC who underwent curative surgery from 2017 to 2021, employing propensity score matching (PSM) analysis.

Survival Impact of Adjuvant Nivolumab Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemotherapy with Docetaxel Plus 5-Fluorouracil and Cisplatin.

Background: The efficacy of adjuvant nivolumab following neoadjuvant chemotherapy in managing locally advanced esophageal cancer remains unclear. This study evaluated the survival benefits of adjuvant nivolumab after neoadjuvant chemotherapy with a docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

Methods: This single-center, retrospective study included 439 consecutive patients with locally advanced ESCC who underwent radical esophagectomy following neoadjuvant DCF chemotherapy.

Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer.

The GLOW and SPOTLIGHT trials have demonstrated the efficacy of chemotherapy plus zolbetuximab for HER2-negative, claudin-18 isoform 2 (CLDN18.2)-positive unresectable advanced or recurrent gastric cancer (AGC)/gastroesophageal junction cancer. However, data on adverse events in real-world clinical practice are still insufficient.

Robotic and laparoscopic gastrectomy for gastric cancer: comparative insights into perioperative performance and three-year survival outcomes.

Background: The primary treatment for gastric cancer (GC) is surgical resection, particularly for locally advanced cases. While laparoscopic gastrectomy (LG) has shown short- and long-term benefits, robotic gastrectomy (RG) offers enhanced precision and may lead to better outcomes, especially in advanced-stage disease.

Methods: This retrospective study analyzed data from 1538 patients with pathological Stage I-III GC who underwent RG or LG between 2014 and 2021.

Prognostic impact of lateral sentinel lymph node biopsy using indocyanine green on oncological outcomes for clinical stage II/III lower rectal cancer without suspected lateral lymph node metastasis.

Purpose: Sentinel lymph node biopsy (SLNB) can detect occult nodal metastasis. We have previously reported the safety and feasibility of indocyanine green (ICG)-guided SLNB for clinical stage II/III lower rectal cancer (RC). However, little is known about the influence of lateral pelvic SLNB using ICG on oncological outcomes.

Survival Impact of Inflammation-based Prognostic Scores in Metastatic or Unresectable Esophageal Cancer Treated With Pembrolizumab Plus Chemotherapy.

Pembrolizumab plus chemotherapy has been indicated as the first-line treatment for metastatic or unresectable locally advanced esophageal cancer. However, pretreatment biomarkers for predicting clinical outcomes remain unclear. We investigated the predictive value of inflammation-based prognostic scores in patients treated with pembrolizumab and chemotherapy.

Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.

Background/aim: CheckMate 577 evaluated adjuvant nivolumab therapy after neoadjuvant chemoradiotherapy and surgery for esophageal cancers. However, the efficacy of this treatment in patients who received neoadjuvant chemotherapy remains unknown. This study investigated the short-term outcomes of adjuvant nivolumab therapy in patients with advanced esophageal squamous cell carcinoma post-neoadjuvant chemotherapy.

Clinical Impact of Transanal Drainage Tube on Anastomosis Leakage Following Minimally Invasive Resection Without Diverting Stoma in Patients With Rectal Cancer: A Propensity Score-matched Analysis.

Objectives: As one of the most serious complications of rectal cancer (RC) surgery, preventing anastomotic leakage (AL) is crucial. Several studies have suggested a positive role of the transanal drainage tube (TaDT) in AL prevention. However, whether TaDT is beneficial for AL in patients with RC remains controversial.

Impact of regional lymph node metastasis on pulmonary metastasis as the first recurrence site.

Little is known about the impact of regional lymph node metastasis (LNM) on the first recurrence sites following curative colorectal cancer (CRC) surgery. The present study aimed to clarify the relationship between regional LNM stratified by N status and the first recurrence pattern in patients with stage I-III CRC. We performed a retrospective analysis of 1181 consecutive patients with stage I-III CRC who underwent curative surgery between 2010 and 2018.

Lymph node metastasis in T1 colorectal cancer: Risk factors and prediction model.

Endoscopic resection is typically performed for early T1 stage colorectal cancer (T1 CRC). Additional surgery is subsequently recommended based on pathological findings; however, the current criteria may result in overtreatment. The present study aimed to re-examine the reported risk factors for lymph node (LN) metastasis in T1 CRC and develop a prediction model using a large multi-institutional dataset.

Single-incision laparoscopic surgery for intestinal intussusception due to neuroendocrine tumor.

Background: Small intestinal neuroendocrine tumor (NET) is uncommon, but intestinal intussusception caused by NET is even rare. We report a rare case of single-incision laparoscopic surgery (SILS) for intestinal intussusception due to NET G1.

Case Presentation: A 72-year-old woman presented with vomiting, diarrhea, and abdominal pain.

[A Case of Advanced Gastric Cancer in Which Tumor Relapse Was Observed after Discontinuation of Nivolumab Due to Complete Response, and for Which Re-Administration Was Initiated].

A 61-year-old male was diagnosed with unresectable advanced gastric cancer(cT4b[SI; panc], N+, M0, cStage ⅣA). However he was administered S-1 plus oxaliplatin as a primary treatment and ramucirumab plus paclitaxel as a secondary treatment, the primary tumor and lymph nodes were enlarged. We judged PD and switched to the third-line treatment with nivolumab.